TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male adults of age of 18-45 years.~* Measles immune, as determined by IgG antibody levels.~* Healthy as supported by medical history, physical examination and laboratory evaluation on preset parameters.~* Signed informed consent for participation in trial and for HIV screening.~Exclusion Criteria:~* Medical history of immunodeficiency/suppression or subject with history of close contact with immunocompromised/ immunosuppressed person.~* Chronic administration of immunosuppressants or other immune modifying agents~* Acute febrile illness or suspected measles illness or acute infectious disease~* Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, psychiatric, cardiovascular, neurological, hepatic or renal functional abnormality which in the opinion of the investigator, might interfere with the study objectives~* History of seizure disorders~* Major congenital defects~* Thrombocytopenia or known bleeding disorders 8. History of a previous severe allergic reaction~* Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen~* Known hypersensitivity to any component of the study vaccine

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PMV via Puffhaler® Device (Type: EXPERIMENTAL): The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
- PMV via SoloventTM device (Type: EXPERIMENTAL): The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
- Licensed Subcutaneous Measles Vaccine (Type: ACTIVE_COMPARATOR): Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enoxaparin as Treatment for Vulvodynia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women with vulvodynia~Exclusion Criteria:~* women without vulvodynia

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma or adenocarcinoma of the thoracic esophagus~  * Carcinoma of the gastroesophageal junction (i.e., Siewert staging system type I disease) allowed~* Locally advanced disease~  * Obstructive tumors are considered locally advanced disease~ * Meets 1 of the following staging criteria:~    * T3, N0 disease~   * T1-3, N1 disease~   * T4, N0-1 disease~* Resectable disease~  * No T4 (unequivocal organ involvement) disease that cannot be resected with curative intent~* No airway infiltration in case of tumors of the upper third of the thoracic esophagus~* No cervical esophageal carcinoma~* No distant metastasis, including stage M1a (celiac node involvement) by fine-needle aspiration or biopsy~PATIENT CHARACTERISTICS:~* WHO performance status 0-1~* Creatinine clearance \> 60 mL/min~* Bilirubin normal~* Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)~* AST ≤ 1.5 times ULN~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* No other malignancy within the past 5 years except nonmelanomatous skin cancer or adequately treated in situ cervical cancer~* No severe or uncontrolled cardiovascular disease including, but not limited to, any of the following:~  * New York Heart Association class III or IV congestive heart failure~ * Unstable angina pectoris~ * Myocardial infarction within the past 3 months~ * Significant arrhythmias~* No psychiatric disorder that would preclude study compliance~* No active uncontrolled infection~* No serious underlying medical condition that, in the opinion of the investigator, would interfere with study participation (e.g., uncontrolled diabetes mellitus or active autoimmune disease)~* No peripheral neuropathy \> grade 1~* No contraindications to corticosteroids~* No known hypersensitivity to any component of the study drugs~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* No prior radiotherapy to the chest~* No participation in another clinical trial within the past 30 days~* No other concurrent experimental drugs or anticancer therapy~* No concurrent drugs contraindicated for use with the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meibomian Gland Dysfunction Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of meibomian gland obstruction in both eyes~* dry eye symptoms per DEQ-5~Exclusion Criteria:~* active ocular infection~* previous LipiFlow treatment~* beginning new oral or other systemic medications within prior 3 months~* beginning new or changing dosages of ocular medications within prior 3 months~* previous ocular surgery, trauma, herpes, recurrent inflammation, punctal plugs in prior 3 months~* habitual contact lens wear in prior 3 months~* women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subject Treatment (Type: EXPERIMENTAL): All subjects will receive light based (sham) treatment, then all subjects will receive LipiFlow treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PictureRx: Improving Medication Safety in Health Disparity Populations

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prescribed one or more prescription medications~Exclusion Criteria:~* Too ill to complete informed consent process

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PictureRx (Type: EXPERIMENTAL): PictureRx medication history platform
- Usual care (Type: NO_INTERVENTION): Usual medication history process

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A primary diagnosis of MDD~* Depressive symptoms for at least 30 days before the screening visit.~Exclusion Criteria:~* Treatment with DVS SR at any time in the past.~* Known hypersensitivity to venlafaxine~* Significant risk of suicide based on clinical judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Psychiatric Diagnosis of generalized anxiety disorder (GAD)~* Outpatients~* Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis for GAD~* Clinical Global Impression (CGI) of Severity Score of at least moderate~* Sheehan Disability Scale (SDS) Global Functioning Impairment Score \>= 12~Exclusion Criteria:~* Pregnancy or breast feeding~* Serious medical illness~* Other primary psychiatric diagnoses, such as major depressive disorder or substance abuse disorder within the past 6 months~* panic disorder, post-traumatic stress disorder (PTSD), or eating disorder in the last year~* lifetime history of bipolar or psychosis~* Any unstable serious medical condition for which duloxetine would not be allowed~* Any use of medications that are not allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* male and female subjects aged 18 to 75 years (inclusive) with a diagnosis of UC ≥ 90 days before screening;~* active UC defined as a total Mayo Score of 4 to 10 (inclusive), at baseline, with a Mayo endoscopic subscore (MES) ≥ 2 confirmed by a central reader;~* baseline fecal calprotectin ≥ 250 μg/g;~* biologic-naïve or having stopped biologic therapy ≥ 8 weeks before the start of the study;~* 5-aminosalicylates must be stable for ≥ 1 month prior to randomization.~Key Exclusion Criteria:~* Crohn's disease (CD), indeterminate colitis, or presence or history of fistula with CD;~* a history of toxic megacolon, abdominal abscess, symptomatic colonic stricture, or stoma;~* history of or at imminent risk of colectomy;~* history of or current colonic dysplasia ;~* recent history (within 2 years prior to randomization) or current adenomatous colonic polyps;~* treatment with an immunosuppressant within 3 months of randomization;~* bacterial or parasitic pathogenic enteric infection;~* live virus vaccination within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NX-13 250mg IR (Type: EXPERIMENTAL): Oral
- NX-13 500mg IR (Type: EXPERIMENTAL): Oral
- NX-13 500mg MR (Type: EXPERIMENTAL): Oral
- Placebo (Type: PLACEBO_COMPARATOR): Oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient (or patient's legally acceptable representative) capable to provide a written, dated, and signed informed consent prior to any study related procedure~* Non-infected delayed-union fracture of a long bone of minimum 3 months and maximum 7 months (+/- 2 weeks)~Exclusion Criteria:~* Fracture interline larger than 2.5 cm~* Insufficient fracture stability~* Multifocal fracture~* Positive serology for hepatitis B, hepatitis C, Human Immunodeficiency Virus (HIV)~* Current or past medical disease that could interfere with the evaluation of the safety and efficacy, as judged by the investigator~* Severe renal or hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ALLOB® Implantation (Type: EXPERIMENTAL): One arm: ALLOB® Implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, ≥ years of age.~* Moderate to severe rheumatoid arthritis of ≥ 6 months duration.~* Receiving treatment on an outpatient basis.~* Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.~* On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start.~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.~* Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.~* Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.~* Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.~* Prior history of or current inflammatory joint disease other than rheumatoid arthritis.~* History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations.~Other inclusion and exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 162 mg sc (Type: EXPERIMENTAL): Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
- Placebo sc (Type: PLACEBO_COMPARATOR): Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve or -experienced adult male or female participants with confirmed chronic hepatitis C (CHC), genotype 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN ± ribavirin (RBV) according to standard of care and in line with the current local label~* If RBV was co-administered with the ABBVIE REGIMEN, it had to be prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy)~* Participants had to voluntarily sign and date an informed consent form prior to inclusion into the study~* Participants must not have participated or intended to participate in a concurrent interventional therapeutic trial~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Participants with HCV genotype 1 or 4 (Type: None): Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* surgical extraction of \> 2 third molars with at least 1 complete or partial mandibular bony extraction~Exclusion Criteria:~* allergic response to aspirin, NSAIDs, acetaminophen or hydrocodone~* use of aspirin or other analgesics within 48 hours prior to surgery~* current or recent history of drug or alcohol abuse~* any medication for treatment of chronic pain~* clinically significant abnormality on screening laboratory test active or recent history of peptic ulcer disease or GI bleeding~* prior abdominal surgery, except uncomplicated appendectomy~* any other surgical procedure within 30 days before administration of study drug~* pregnancy or breastfeeding~* untreated hypertension; SBP \> 140 mmHg or DBP \> 95 mmHg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- N1539 15 mg (Type: EXPERIMENTAL): None
- N1539 30 mg (Type: EXPERIMENTAL): None
- N1539 60 mg (Type: EXPERIMENTAL): None
- Motrin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 to 65 years subjects from outpatients;~2. Subjects currently meet the Diagnostic and Statistical Manual of Manual Disorders, fifth Edition(DSM-5) criteria for MDD with either single or recurrent episodes (296.2/296.3) without psychotic characteristics;~3. Subjects has a total score of the Montgomery- Åsberg Depression Scale (MADRS) ≥26 points at screening;~4. Subjects has a clinical Global Impression -severity illness (CGI-S) score≥4 points at screening~Exclusion Criteria:~1. Allergic or known to be allergic to venlafaxine and desvenlafaxine;~2. Subjects with MDD who were not responsive to the previous venlafaxine treatment with sufficient amount and duration and to at least two different mechanisms of action antidepressants with adequate amount and duration in the past;~3. There is a clear suicide attempt or behavior and score of the 10th item (suicidal ideation) in MADRS scale is 4 points or greater;~4. Pregnant or lactating women,women who have a planned pregnancy in the near future;~5. Subjects meet the diagnostic criteria for other psychotic disorders(except for MDD) in DSM-5, such as Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders, Obsessive-Compulsive and related Disorders, post-traumatic stress disorder, separation disorders, anorexia nervosa or bulimia and personality disorder;~6. Subjects who meet the diagnostic criteria for substance or alcohol abuse (excluding nicotine or caffeine) 6 months prior to the screening;~7. MDD secondary to other mental illnesses or physical illnesses;~8. Those with a history of seizures (except for convulsions caused by febrile seizures in children).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LY03005 extended-release tablets 80 mg group (Type: EXPERIMENTAL): orally once a day
- LY03005 extended-release tablets 160 mg group (Type: EXPERIMENTAL): orally once a day
- Placebo group (Type: PLACEBO_COMPARATOR): orally once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete